Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2003-01-03
2009-11-03
Kapushoc, Stephen (Department: 1634)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S006120, C536S023100, C536S024300, C536S024330
Reexamination Certificate
active
07611870
ABSTRACT:
The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting is indicative of an increased risk of developing cancer. The method can include analyzing genomic DNA from the sample for altered methylation of the IGF2 gene. The altered methylation for example includes hypomethylation of a differentially methylated region of IGF2, corresponding to SEQ ID NO:1 or a polymorphism thereof. The method can be performed on a subject having no apparent or suspected hyperproliferative disorder such as cancer.
REFERENCES:
patent: 5552277 (1996-09-01), Nelson et al.
patent: 5786146 (1998-07-01), Herman et al.
patent: 6235474 (2001-05-01), Feinberg
patent: WO 2004/010850 (2004-02-01), None
Feinberg et al., “The history of cancer epigenetics”, Nature Reviews Cancer, vol. 4, pp. 1-11, Feb. 2004.
Ransohoff et al., “Developing molecular markers for cancer”, Science, vol. 299, pp. 1679-1680, Mar. 2003.
Ohlsson, “Loss of IGF2 imprinting: mechanisms and consequences”, Novartis Found. Symp., vol. 262, pp. 108-121, 2004.
Jirtle, “IGF2 loss of imprinting: a potential heritable risk factor”, Gastroenterology, vol. 126, pp. 1190-1193, Apr. 2004.
Woodson et al., “Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women”, Journal of the National Cancer Institute, vol. 96, pp. 407-410, Mar. 2004.
Kaneda et al., “Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk”, Cancer Research, vol. 65, pp. 11236-11240, Dec. 2005.
Khoury et al., “Population screening in the age of genomic medicine”, New England Journal of Medicine, vol. 348, pp. 50-58, Jan. 2003.
Cruz-Correa et al., “Loss of imprinting of the IGF2 gene is a diffuse colorectal molecular abnormality which may predict colorectal cancer risk”, Gastroenterology, vol. 122, No. 4, Suppl. 1, p. A-33, Apr. 2002.
Cruz-Correa et al., “Loss of imprinting of the IGF2 gene is a diffuse colorectal molecular abnormality that may predict colorectal cancer risk”, Journal of Investigative Medicine, vol. 50, No. 2, p. 161A, Mar. 2002.
Cui et al., “Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability”, Nature Medicine, vol. 4, No. 11, pp. 1276-1280, Nov. 1998.
Cui et al., “Loss of IGF2 imprinting: a potential marker of colorectal cancer risk”, Science, vol. 299, pp. 1753-1755, Mar. 14, 2003.
Fletcher, “Screening colonoscopy: option of preference?”, Gastrointestinal Endoscopy, vol. 51, No. 5, pp. 624-627, 2000.
Reik et al., “IGF2 imprinting in development and disease”, International Journal of Developmental Biology, vol. 44, pp. 145-150, 2000.
Fukuzawa et al., “Epigenetic differences between Wilms' tumors in white and east-Asian children”, The Lancet, vol. 363, pp. 446-451, Feb. 2004.
Ravenel, J.D., et al.,J. Natl. Cancer Inst. vol. 93, 2001, pp. 1698-1703.
Rainer et al.,Nature, vol. 362, 1993, pp. 747-749.
Feinberg, A.P. and Vogelstein, B., “Hypomethylation Distinguishes Genes of Some Human Cancers From Their Normal Counterparts,”Nature(Lond.), vol. 301, 1983, pp. 89-92.
Feinberg, A.P., et al. “Reduced Genomic 5-Methylcytosine Content in Human Colonic Neoplasia,”Cancer Res., vol. 48, 1988, pp. 1159-1161.
Ogawa, O., et al., “Relaxation of Insulin-Like Growth Factor II Gene Imprinting Implicated in Wilm's Tumour,”Nature(Lond.), vol. 362, 1993, pp. 749-751.
Steenman, M. J., et al., Loss of Imprinting of IGF2 is Linked to Reduced Expression and Abnormal Methylation of H19 in Wilms' Tumour,Nat. Genet, vol. 7, 1994, pp. 433-439.
Uegima, H., et al., “Hot-Stop PCR: a Simple and General Assay for Linear Quantitation of Allele Ratios,”Nat. Genet., vol. 25, 2000, pp. 375-376.
Sullivan, M.J., et al., “Relaxation of IGF2 Imprinting in Wilms Tumours Associated with Specific Changes in IGF2 Methylation,”Oncogene, vol. 18, 1999, pp. 7527-7534.
Moore, T, et al., Multiple Imprinted Sense and Antisense Transcripts, Differential Methylation and Tandem Repeats in a Putative Imprinting Control Region Upstream of MouseIGF2, Proc. Natl. Acad. Sci. USA, vol. 94, Nov. 1997, pp. 12509-12514.
Issa, Jean-Pierre J., et al., “Switch from Monoallelic to Biallelic HumanIGF2Promoter Methylation During Aging and Carcinogenesis.”Proc. Natl. Acad. Sci. USA, vol. 93, Oct. 1996, pp. 11757-11762.
Nakagawa, H., et al., “Loss of Imprinting of the Insulin-Like Growth Factor II Gene Occurs by Biallelic Methylation in a Core Region ofH19-Associated CTCF-binding Sites in Colorectal Cancer,”Proc. Natl. Acad. Sci. USA, Jan. 16, 2001, vol. 98, No. 2, pp. 591-596.
Lee, M.P., et al., “Loss of Imprinting of a Paternally Expressed Transcript, with Antisense Orientation to KvLQT1, Occurs Frequently in Beckwith-Wiedemann Syndrome and is Independent of Insulin-Like Growth Factor II Imprinting,”Proc. Natl. Acad. Sci. USA., vol. 96, Apr. 1999, pp. 5203-5208.
Cui, Hengmi, et al., “Loss of Imprinting ofInsulin-like Growth Factor-IIin Wilms' Tumor Commonly Involves Altered Methylation but not Mutations ofCTCFor Its Binding Site1,”Cancer Research, vol. 61, Jul. 1, 2001, pp. 4947-4950.
Takai, Daiya, et al., “Large Scale Mapping of Methylcytosines in CTCF-binding Sites in the HumanH19Promoter and Aberrant Hypomethylation in Human Bladder Cancer,”Human Molecular Genetics, vol. 10, No. 23, 2001, pp. 2619-2626.
Bartolomei, M.S., et al., “Epigenetic Mechanisms Underlying the Imprinting of the Mouse H19 Gene,”Genes&Dev. 7(9), Sep. 1993, pp. 1663-1673.
Taniguchi, T., et al., “Epigenetic Changes Encompassing theIGF2/H19Locus Associated with Relaxation ofIGF2Imprinting and Silencing ofH19in Wilms Tumor,”Proc. Natl. Acad. Sci., vol. 92, Mar. 1995, pp. 2159-2163.
Catchpoole, D., et al., “Mutation Analysis ofH19andNAPlL4(hNAP2) Candidate Gene andIGF2DMR2 in Beckwith-Wiedemann Syndrome,”J. Med Genet, 37(3) Mar. 2000, pp. 212-215.
Nishihara, S., et al., “Multipoint Imprinting Analysis in Sporadic Colorectal Cancers With and Without Microsatellite Instability,”Int. J. Oncol., 17(2), Aug. 2000, pp. 317-322.
Hofmann, W.K., et al., “Loss of Genomic Imprinting of Insulin-Like Growth Factor 2 is Strongly Associated with Cellular Proliferation in Normal Hematopietic Cells,”Exp. Hematol, 30(4), Apr. 2002, pp. 318-323.
Cui, H., et al., “Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation ofH19andIGF2I,” Cancer Research, 62, Nov. 15, 2002, pp. 6442-6446.
Vu, T.H., et al., Symmetric and Asymmetric DNA Methylation in the Human IGF2-H19 Imprinted Region,Genomics, 64(2) Mar. 1, 2000, pp. 132-143.
Schoenherr, C.J., et al., “CTCF Maintains Differential Methylation at theIgf2/H19Locus,”Nat. Genet, 33(1), Jan. 2003, pp. 66-69.
Bell, A.C., et al., “The Protein CTCF is Required for the Enhancer Blocking Activity of Vertebrate Insulators,”Cell, vol. 98, Aug. 6, 1999, pp. 387-396.
Schneider, D. T., et al., “Multipoint Imprinting Analysis Indicates a Common Precursor Cell for Gonadal and Nongonadal Pediatric Germ Cell Tumors1,”Cancer Research, vol. 61, Oct. 1, 2001, pp. 7268-7276.
Uyeno, S., et al., “IGF2But notH19Shows Loss of Imprinting in Human Glioma1,”Cancer Research, vol. 56, Dec. 1, 1996, pp. 5356-5359.
Yun, K., et al., “Analysis ofIGF2Gene Imprinting in Breast and Colorectal Cancer by Allele Specific-PCR,”Journal of Pathology, vol. 187, 1999, pp. 518-522.
Bell, A. C. and Felsenfeld, G., “Methylation of a CTCF—dependent Boundary Controls Imprinted Expression of the Igf2 Gene,”Na
DLA Piper (LLP) US
Kapushoc Stephen
The Johns Hopkins University School of Medicine
LandOfFree
Methods for identifying cancer risk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying cancer risk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying cancer risk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093193